Case study

Discovering biomarkers in cerebrospinal fluid EVs

The institute wanted to identify diagnostic biomarkers for neurodegenerative diseases by analysing proteins in extracellular vesicles from cerebrospinal fluid. Shotgun proteomics data contained missing values and required rigorous processing.

Our Approach

We applied rigorous data processing, statistical analysis and biological context assessment to identify diagnostic biomarkers.

  • Data processing & statistical analysis: Filtered and imputed timsTOF data, performed pairwise comparisons and produced a detailed report with differentially expressed proteins.
  • Quality control: Conducted quality control to remove samples with missing values or unclear phenotypes.
  • Biological relevance & knowledge transfer: Assessed biological relevance of candidates through literature searches, suggested follow‑up analyses and held a knowledge‑transfer meeting.

The Outcome

  • Delivered an evidence‑based list of differentially expressed proteins and contextualised them biologically.
  • Validated quality control and statistical approaches to maximise scientific value within a limited budget.
  • Provided guidance for future experiments and ensured knowledge transfer.

Why It Matters

Reliable biomarker discovery pipelines accelerate translational research. This project shows how expert analysis of proteomics data can reveal diagnostic candidates and guide further research.

Let’s discuss how we can turn your data into real scientific impact.

Contact us >

Beyond animal testing in drug development

Beyond animal testing in drug development

For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])

How spatial biology improves clinical trial success in oncology

How spatial biology improves clinical trial success in oncology

Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.